INT55479

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.81
First Reported 1994
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 13
Total Number 13
Disease Relevance 6.10
Pain Relevance 1.53

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Epo) aging (Epo) extracellular region (Epo)
Anatomy Link Frequency
blood 4
sinus 1
heart 1
Epo (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Glutamate 5 100.00 Very High Very High Very High
Enkephalin 1 100.00 Very High Very High Very High
Neurotransmitter 1 100.00 Very High Very High Very High
Peripheral nervous system 3 99.80 Very High Very High Very High
anesthesia 6 94.60 High High
Hippocampus 4 93.64 High High
Dismenorea 2 90.40 High High
cytokine 17 89.56 High High
ischemia 52 89.52 High High
cva 6 87.92 High High
Disease Link Frequency Relevance Heat
Stroke 15 99.48 Very High Very High Very High
Neurodegenerative Disease 4 99.00 Very High Very High Very High
Sprains And Strains 2 98.88 Very High Very High Very High
Heart Rate Under Development 21 97.76 Very High Very High Very High
Hyperthyroidism 29 97.72 Very High Very High Very High
Arrhythmias 2 Under Development 9 97.08 Very High Very High Very High
Injury 2 96.88 Very High Very High Very High
Erythrocytosis 9 92.88 High High
Tricuspid Valve Insufficiency 17 91.48 High High
Volume Depletion And Dehydration 2 91.00 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Beta-2 sympathomimetics, such as terbutaline, have been shown to alter erythropoietin (EPO) secretion in animal studies.
Localization (secretion) of erythropoietin
1) Confidence 0.81 Published 1994 Journal Biochem. Med. Metab. Biol. Section Abstract Doc Link 7993659 Disease Relevance 0.18 Pain Relevance 0.16
Beta-2 sympathomimetics, such as terbutaline, have been shown to alter erythropoietin (EPO) secretion in animal studies.
Localization (secretion) of EPO
2) Confidence 0.81 Published 1994 Journal Biochem. Med. Metab. Biol. Section Abstract Doc Link 7993659 Disease Relevance 0.18 Pain Relevance 0.16
At 30 minutes before inhibiting the blood flow and after releasing the inhibited blood flow, 100 U/kg of recombinant human erythropoietin (rhEPO) was administered via the inferior vena cava and the abdominal cavity, and then the tissues and blood samples were extracted at 6 hours and 24 hours after the release.
Localization (releasing) of rhEPO in blood
3) Confidence 0.80 Published 2010 Journal Hinyokika Kiyo Section Abstract Doc Link 20808070 Disease Relevance 0.40 Pain Relevance 0.18
At 30 minutes before inhibiting the blood flow and after releasing the inhibited blood flow, 100 U/kg of recombinant human erythropoietin (rhEPO) was administered via the inferior vena cava and the abdominal cavity, and then the tissues and blood samples were extracted at 6 hours and 24 hours after the release.
Localization (releasing) of erythropoietin in blood
4) Confidence 0.70 Published 2010 Journal Hinyokika Kiyo Section Abstract Doc Link 20808070 Disease Relevance 0.40 Pain Relevance 0.18
As erythropoietin having direct and indirect effect on nerve cells, enhances antioxidotic enzyme production, antagonizes glutamate's cytotoxic action, metabolizes free radicals, normalizes cerebral blood flow, affects neurotransmitters release and stimulates neoangiogenesis.
Localization (release) of erythropoietin in blood associated with neurotransmitter and glutamate
5) Confidence 0.67 Published 2007 Journal Clin Neurol Neurosurg Section Abstract Doc Link 17624659 Disease Relevance 0.58 Pain Relevance 0.43
Measurement of Serum EPO Levels in G-CSF-Treated Human Donors
Localization (Measurement) of EPO
6) Confidence 0.65 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2852409 Disease Relevance 0.25 Pain Relevance 0.04
Fractions of GFP+c-Kit+ cells colocalizing with specific markers MAP-2, GFAP, Neu-N, and Musashi-1 in the EPO+G-CSF-treated mice (?
Localization (colocalizing) of EPO
7) Confidence 0.65 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2852409 Disease Relevance 0.23 Pain Relevance 0.12
Erythropoietin use
Localization (use) of Erythropoietin
8) Confidence 0.46 Published 2008 Journal Nephrology Dialysis Transplantation Section Body Doc Link PMC2568010 Disease Relevance 0.31 Pain Relevance 0
After adjustment for potential confounders (sex, age, use of erythropoietin or parenteral iron, frequency of NSAID use, smoking, drinking alcohol, heart failure, arterial hypertension, diabetes mellitus, chronic obstructive pulmonary disease, and use of anticoagulants, antiplatelet agents, beta-blockers, angiotensin-converting enzyme inhibitors or diuretics), the only significant association that remained was between gastrointestinal bleeding and use of NSAIDs (OR adjusted = 5.8; 95% CI, 1.3-26.9; p=0.024).
Localization (use) of erythropoietin in heart
9) Confidence 0.16 Published 2009 Journal J. Nephrol. Section Body Doc Link 19662606 Disease Relevance 0.12 Pain Relevance 0
Persistent erythropoietin secretion from the diseased and chronically ischemic native kidneys does not conform to the normal feedback regulation, thereby establishing a form of "tertiary hypererythropoietinemia."
Localization (secretion) of erythropoietin
10) Confidence 0.12 Published 2003 Journal Kidney Int. Section Abstract Doc Link 12631334 Disease Relevance 1.14 Pain Relevance 0.13
Here, we demonstrate that a L. lactis strain containing the nisBTC genes effectively dehydrates and secretes a wide range of medically relevant nonlantibiotic peptides among which variants of adrenocorticotropic hormone, vasopressin, an inhibitor of tripeptidyl peptidase II, enkephalin, luteinizing hormone-releasing hormone, angiotensin, and erythropoietin.
Localization (secretes) of erythropoietin associated with enkephalin and sprains and strains
11) Confidence 0.04 Published 2005 Journal Biochemistry Section Abstract Doc Link 16171398 Disease Relevance 0.19 Pain Relevance 0.10
Compensatory mechanisms in the form of increase in cardiac output (CO), PaO2, 2,3 diphosphoglycerate levels, rightward shift in the oxygen dissociation curve (ODC), decrease in blood viscosity and release of renal erythropoietin, get activated to variable degrees to maintain tissue oxygenation and offset the decreases in arterial O2 content.
Localization (release) of erythropoietin in blood
12) Confidence 0.02 Published 2010 Journal Indian Journal of Anaesthesia Section Abstract Doc Link PMC2991646 Disease Relevance 0.60 Pain Relevance 0.04
Thyroid hormone (particularly T3) increases heart rate and left ventricular contractility, decreases systemic vascular resistance, increases sodium re-absorption and erythropoietin secretion, and raises stroke volume up to 300%.1) However, during thyrotoxicosis, atrial fibrillation or sinus tachycardia can occur, which may be caused by a calcium circulation distrubance to heart cells and structural changes in the heart.1-3) In case that atrial fibrillation or sinus tachycardia lasts for an extended period due to uncontrolled thyrotoxicosis, 6% of the patients experience heart failure, and among these cases half are accompanied by LVD; this is termed tachycardia induced cardiomyopathy.3)4)
Localization (secretion) of erythropoietin in sinus associated with heart rate under development, left ventricular dysfunction, cv general 4 under development, stroke, arrhythmias 2 under development, hyperthyroidism and coronary heart disease
13) Confidence 0.02 Published 2010 Journal Korean Circulation Journal Section Body Doc Link PMC2893366 Disease Relevance 1.53 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox